Clinical trials: Antibody-mediated Rejection
Heart Transplant, Pediatric Heart Transplant
Non-invasive Prediction of EArly Cardiac rEjection
Acute rejection remains a major cause of morbidity and mortality in pediatric patients after heart transplant. In order to screen for rejection, most centers perform heart catheterizations with endomyocardial biopsies frequently…
- Conditions
- Heart Transplant, Pediatric Heart Transplant, Rejection, Cardiac MRI
- Trial name
- PEACE (NCT07770659)
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vanderbilt University Medical Center
Graft Rejection, Kidney Transplantation
TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Response to Extracorporeal Photo-aphereSiS
With this project, the research team aims to identify the molecular pathways associated with the response to extracorporeal photonchemioapheresis (ECP) in kidney or lung transplant patients suffering from chronic rejection, by…
- Conditions
- Graft Rejection, Kidney Transplantation, Lung Transplantation, Antibody-Mediated Rejection
- Trial name
- TRACKLESS (NCT07316829)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Antibody Mediated Rejection After Kidney Transplantation
Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity
Humoral rejection of kidney transplants is responsible for a large number of kidney graft losses in a context of increasing shortage.
- Trial name
- B-KiMi (NCT07134491)
- Testing
- Piece of kidney removal, Stool collection, Blood collection
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection, Kidney Transplantation
Incidence, Course and Outcome of ABMR in Kidney Transplantation
Rationale: Despite improved patient and graft survival in renal transplant recipients, still 20% of the patients reaches end-stage renal disease within 5 years after transplantation.
- Conditions
- Antibody-mediated Rejection, Kidney Transplantation, Immunosuppression
- Trial name
- PROCARE2 (NCT05140018)
- Testing
- Kidney Transplantation, Immunosuppression, Nephrectomy (kidney donation)
- Where
- 6 sites in Netherlands
- Volunteers
- 225 people
- Sponsor
- University Medical Center Groningen
Chronic Antibody-mediated Transplant Rejection
Bortezomib in Rejection of Kidney Transplants
The purpose of the study is to assess the efficacy of bortezomib, in association with steroids, plasma exchange, and polyclonal intravenous immunoglobulins, in the treatment of chronic antibody mediated rejection due to donor…
- Trial name
- TRIBUTE (NCT02201576)
- Testing
- Bortezomib, Plasma exchanges and intravenous immunoglobulins
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibody-mediated Rejection
Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response
In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological characteristics such as creatinine, proteinuria…
- Trial name
- NCT03430414
- Testing
- Transcriptome Analysis
- Volunteers
- 50 people
- Sponsor
- Thomas Mueller
Antibody-mediated Rejection, Microvascular Inflammation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed antibody-mediated rejection (AMR) or microvascular inflammation (MVI).
- Trial name
- NCT07444489
- Testing
- Felzartamab
- Where
- 14 sites in United States
- Volunteers
- 201 people
- Sponsor
- Biogen
Antibody-mediated Rejection
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
This multi-center study is an investigator-driven randomized controlled parallel group open-label clinical trial designed to evaluate the efficacy of addition of anti-IL-6 antibody tocilizumab (TCZ) to the standard of care (SOC)…
- Trial name
- INTERCEPT (NCT04561986)
- Testing
- Tocilizumab
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 50 people
- Sponsor
- Vastra Gotaland Region
Kidney Transplantation
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Organ transplantation offers the only hope for a normal life for patients with end-stage renal disease on dialysis (ESRD). For the highly-sensitized patient, patients with antibodies to human leukocyte antigens (HLA)…
- Trial name
- NCT01134510
- Testing
- C1 Esterase Inhibitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanley Jordan, MD
Antibody-mediated Rejection
A Pilot Trial of Clazakizumab in Late ABMR
This bi-center study (Medical University of Vienna \& Charité Berlin) is an investigator-driven pilot trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy (preliminary assessment) of…
- Trial name
- NCT03444103
- Testing
- Clazakizumab / Clazakizumab
- Where
- 2 sites in Austria, Germany
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Antibody Mediated Rejection
Study of SG301 for Renal AMR After Transplantation
To evaluate the safety and tolerability of SG301 injection in patients with antibody-mediated rejection (AMR) after renal transplantation.
- Trial name
- NCT07764627
- Testing
- SG301 Injection
- Where
- 7 sites in China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Kidney Transplant Rejection
Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
This is a pilot study to determine if extended release Envarsus at an optimal level is just as effective as more invasive standard therapies for subclinical (mild) AMR (antibody mediated rejection) in kidney transplant patients.
- Trial name
- NCT03380936
- Testing
- Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Colorado, Denver
Kidney Transplant Rejection
ddcfDNA in Kidney Transplant Recipients
The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation.
- Trial name
- NCT06013358
- Testing
- AlloSeq cfDNA
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Antibody-mediated Rejection
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
In this study, researchers will learn more about the use of felzartamab in kidney transplant patients who have antibody-mediated rejection, also known as AMR. Kidney transplants can save lives for people with kidney failure.
- Trial name
- TRANSCEND (NCT06685757)
- Testing
- Felzartamab
- Where
- 56 sites in United States, Argentina and 10 more
- Volunteers
- 132 people
- Sponsor
- Biogen
Interventional
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)
Transplant rejection is one of the biggest limitations in renal transplant procedures, where the kidney can undergo an acute, late acute, or chronic transplant rejection.
- Trial name
- NCT03585855
- Testing
- MSC transplantation
- Where
- Slovenia
- Volunteers
- 4 people
- Sponsor
- University Medical Centre Ljubljana
Kidney Transplant Rejection
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Antibody mediated rejection (ABMR) is a major cause of graft loss after kidney transplantation (KT) and is mainly associated with preformed anti-HLA donor specific antibodies (DSAs) (phenotype 1) or de novo DSAs (dnDSAs)…
- Trial name
- BELA-M-R (NCT06291103)
- Testing
- Conversion to Belatacep, Standard of care treatment (SOC regimen) with Tacrolimus
- Where
- France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Rouen
Antibody-mediated Rejection, Kidney Tranplant
The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation
Renal transplantation is the best choice for the treatment of end-stage renal disease, but the long-term survival of the graft is still remains a challenge.
- Trial name
- NCT05913596
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Kidney Transplant
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the…
- Trial name
- NCT05456243
- Testing
- Low dose adipose tissue derived mesenchymal stromal cells (A-MSC), High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Antibody-mediated Rejection, NMO Spectrum Disorder
Biorepository and Registry for Plasma Exchange Patients
Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies.
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Trial name
- NCT05004493
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Charles M Knudson
Lung Transplant Rejection, Antibody-mediated Rejection
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung…
- Trial name
- NCT03805178
- Testing
- Belatacept, Carfilzomib
- Sponsor
- Duke University